Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialLancet Diabetes Endocrinol 2021 Oct 04;[EPub Ahead of Print], N Jongs, T Greene, GM Chertow, JJV McMurray, AM Langkilde, R Correa-Rotter, P Rossing, CD Sjöström, BV Stefansson, RD Toto, DC Wheeler, HJL Heerspink
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.